Patients should discontinue anti-platelet therapy at least 3 days before the injection procedure. Patients on anti-coagulant therapy need to be managed appropriately to decrease the risk of bleeding.

BOTOX is indicated for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and older.

Tell your health care provider if you are taking blood thinners or medicines that can interfere with the clotting of blood, such as aspirin or warfarin. These medicines might make it more likely that you will experience bruising or bleeding at the injection site.

Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles.

Do not use in people who are hypersensitive to any botulinum toxin product or any components of the vial. There should be no infection at the proposed injection sitio.

Can be injected into the bioestimulador de colágeno muscle, intradermally (into the skin dermal layer), or into the bladder wall depending on the condition being treated

After the injections are given, the saline used for bladder wall visualization should be drained. The patient should be observed for at least 30 minutes post-injection.

The duration of post-injection catheterization for those who developed urinary retention is also shown.

Botox Cosmetic is used for aesthetic purposes to smooth wrinkles and improve the appearance of platysma bands.

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There are 2 for onabotulinumtoxinA.

Use of BOTOX for the treatment of overactive bladder in such patients and in patients with multiple recurrent UTIs during treatment should only be considered when the benefit is likely to outweigh the potential risk. 5.13 Urinary Retention in Adults Treated for Bladder Dysfunction

Note: While serious complications are rare at recommended doses, any concerning symptoms should be reported to healthcare providers immediately.

Please see the Patient Information Guide available at for list of these events. Tell your health care provider about any side effects that bother you or do not go away.

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.